Table 1 Baseline clinical characteristics and demographics
|  | Traditional dosing (n = 163) | Genotype-guided dosing (n = 159) |
|---|---|---|
Age, mean (SD), years | 59.4 (14.5) | 58.4 (14.3) |
Male, No. (%) | 88 (54.0) | 100 (62.9) |
Weight, mean (SD), kg | 66.9 (16.8) | 67.3 (14.1) |
Race, No. (%) | ||
 Chinese | 98 (60.1) | 99 (62.3) |
 Malay | 39 (23.9) | 32 (20.1) |
 Indian | 17 (10.4) | 14 (8.8) |
 Others | 9 (5.5) | 14 (8.8) |
CYP2C9 genotype, No./total (%) | ||
 Presence of *3 allele | 11/160 (6.9) | 7/158 (4.4) |
VKORC1–381 genotype, No./total (%) | ||
 C/C | 91/162 (56.2) | 97/159 (61.0) |
 C/T | 47/162 (29.0) | 43/159 (27.0) |
 T/T | 24/162 (14.8) | 19/159 (12.0) |
Indication, No./total (%) | ||
 Atrial fibrillation | 55/160 (34.4) | 61/156 (39.1) |
 Stroke | 11/160 (6.9) | 11/156 (7.1) |
 Deep vein thrombosis | 44/160 (27.5) | 42/156 (26.9) |
 Pulmonary embolism | 19/160 (11.9) | 17/156 (10.9) |
 Left ventricular thrombus | 17/160 (10.6) | 18/156 (11.5) |
 Others | 26/160 (16.3) | 14/156 (9.0) |
Amiodarone, No./total (%) | 3/159 (1.9) | 7/156 (4.5) |
Low-molecular weight heparins, No./total (%) | 78/159 (49.1) | 88/157 (56.1) |
Medical history, No./total (%) | ||
 Stroke | 16/160 (10.0) | 10/157 (6.4) |
 Deep vein thrombosis | 7/160 (4.4) | 4/157 (2.6) |
 Pulmonary embolism | 2/160 (1.3) | 3/157 (1.9) |
 Myocardial infarction | 8/160 (5.0) | 17/157 (10.8) |
 Congestive heart failure | 21/160 (13.1) | 18/157 (11.5) |
 Hypertension | 86/160 (53.8) | 92/157 (58.6) |
 Type 2 diabetes mellitus | 58/160 (36.3) | 56/157 (35.7) |
Centre, No. (%) | ||
 National University Hospital, Singapore | 144 (88.3) | 144 (90.6) |
 University of Malaya Medical Centre, Malaysia | 15 (9.2) | 15 (9.4) |
 Tan Tock Seng Hospital, Singapore | 4 (2.5) | 0 (0.0) |